A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously to Patients With High Lipoprotein(a)

Trial Profile

A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously to Patients With High Lipoprotein(a)

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs ISIS APOARx (Primary)
  • Indications Cardiovascular disorders; Hyperlipoproteinaemias
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ionis Pharmaceuticals; Isis Pharmaceuticals
  • Most Recent Events

    • 22 Sep 2016 Results of this and other dose ranging trial published in an Akcea Therapeutics media release..
    • 22 Sep 2016 According to an Akcea Therapeutics media release, data from this study were published in The Lancet.
    • 21 Sep 2016 Results published in the Lancet
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top